- Home
- BRTX vs NERV Comparison
BRTX vs NERV Comparison
Compare BRTX & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRTX
- NERV
- Stock Information
- Founded
- BRTX 1997
- NERV 2007
- Country
- BRTX United States
- NERV United States
- Employees
- BRTX N/A
- NERV N/A
- Industry
- BRTX Managed Health Care
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- BRTX Health Care
- NERV Health Care
- Exchange
- BRTX Nasdaq
- NERV Nasdaq
- Market Cap
- BRTX 11.2M
- NERV 10.7M
- IPO Year
- BRTX N/A
- NERV 2014
- Fundamental
- Price
- BRTX $1.85
- NERV $1.61
- Analyst Decision
- BRTX Strong Buy
- NERV Hold
- Analyst Count
- BRTX 1
- NERV 1
- Target Price
- BRTX $18.00
- NERV $5.00
- AVG Volume (30 Days)
- BRTX 48.0K
- NERV 15.1K
- Earning Date
- BRTX 03-27-2025
- NERV 04-30-2025
- Dividend Yield
- BRTX N/A
- NERV N/A
- EPS Growth
- BRTX N/A
- NERV N/A
- EPS
- BRTX N/A
- NERV 0.19
- Revenue
- BRTX $401,000.00
- NERV N/A
- Revenue This Year
- BRTX $482.76
- NERV N/A
- Revenue Next Year
- BRTX $212.24
- NERV N/A
- P/E Ratio
- BRTX N/A
- NERV $8.95
- Revenue Growth
- BRTX 175.03
- NERV N/A
- 52 Week Low
- BRTX $1.03
- NERV $1.42
- 52 Week High
- BRTX $2.55
- NERV $3.69
- Technical
- Relative Strength Index (RSI)
- BRTX 53.36
- NERV 41.00
- Support Level
- BRTX $1.72
- NERV $1.54
- Resistance Level
- BRTX $1.85
- NERV $1.89
- Average True Range (ATR)
- BRTX 0.13
- NERV 0.11
- MACD
- BRTX 0.02
- NERV 0.00
- Stochastic Oscillator
- BRTX 50.98
- NERV 22.68
About BRTX BioRestorative Therapies Inc. (NV)
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.